Saturday, 13 July 2013

EDTA chelation therapy and secondary prevention of heart disease

EDTA chelation therapy has been prescribed for patients with cardiovascular disease despite an absence of evidence to support its use. The TACT trial, randomly assigned patients with prior heart attack to infusions of a chelation solution or placebo over one to two years and found a small benefit from chelation in terms of a composite of total mortality, recurrent heart attack, stroke, coronary revascularization, or hospitalization for angina. However the current recommendation is not to use this due to significant limitations of the study (multiple interim analyses, high dropout rates, potential for unmasking). (JAMA 2013; 309:1241).

1 comment:

  1. CSI/ICC should emphatically ban its usage as its a quack practice. It deprives the Illiterate and Ignorant to use his limited resources for proven therapies, as he has already exhausted his resources on Chelation.(upto 60 thousand) If it works wonders as Chelation and Cartography Quacks claim, it should be available at PHC level as it is very cheap, like chloroquin can be dispensed by PHC worker. Qudos to Dr Agarwal for highlighting this topic.